In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative | Zendy

Deborah C. Draghi | Zendy; Bret M. Benton | Zendy; Kevin M. Krause | Zendy; Clyde Thornsberry | Zendy; Chris M. Pillar | Zendy; D.F. Sahm | Zendy

Open Access

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

Author(s) -

Deborah C. Draghi,

Bret M. Benton,

Kevin M. Krause,

Clyde Thornsberry,

Chris M. Pillar,

D.F. Sahm

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn124

Subject(s) - gram , microbiology and biotechnology , medicine , biology , bacteria , genetics

Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research